UNSPSC 51162707: Cartasteine

This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E3N11DY0TA. European Medicines Agency schedules Cartasteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06148MIG. Cartasteine generally arises in the molecular formula C9H14N2O4S2.

UNSPSC 51162707 Cartasteine, a Commodity code, covers parenteral and injectable pharmaceutical products and related clinical services that state and local health and correctional authorities procure to support inpatient and incarcerated patient care. The code encompasses parenteral nutrition solutions (total parenteral nutrition and peripheral parenteral nutrition), intravenous fluids, controlled substances for medical use, naloxone, drug deactivation systems, and associated delivery and monitoring services. State and local buyers under this code include departments of corrections, county health departments, and community health systems. Work solicited includes preparation and delivery of customized PN formulations with rapid turnaround (within 24 hours of order in some cases), pharmacy clinical services such as patient lab monitoring and PN adjustment, and supply chain management across multiple facilities or delivery points.

Recent activity shows issuing bodies spanning state corrections agencies and county health authorities. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, seeking parenteral products and services across eight correctional facilities in three regions, with bids due October 7, 2026, and awards anticipated to multiple contractors (up to three per region) under a contract term running through June 30, 2030. The RFQ emphasizes rapid delivery performance—PN bags within 24 hours of order, other parenteral products within 8 hours—and requires vendors to demonstrate experience preparing and delivering IV solutions and adjusting PN formulations. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The Washington solicitation includes set-aside goals for small, minority-owned, women-owned, and veteran-owned businesses, while the Seminole County procurement did not specify disadvantaged-enterprise set-asides. Recent opportunities surface in Washington and Florida, with work spanning correctional-health parenteral formulation and community health naloxone supply.